AUTHORS
Changming Dong, ZhuoXin Zhang Jr2, Wen Zhang3, Ruan mengyu4, Wei LIU5, Lu-Gui Qiu, PhD6, Dehui Zou, MD7
AFFILIATIONS
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, Tianjin, Tianjin, China
ABSTRACT
Background: Diffuse large B-cell lymphoma (DLBCL) exhibits marked clinical heterogeneity. Despite standard frontline immunochemotherapy, 30%–40% of patients suffer from relapse or refractoriness with poor prognosis. Conventional predictors including IPI and COO classification rely solely on baseline features with limited predictive power. While end-of-treatment PET (EOT-PET) is well validated, the prognostic role of interim PET (iPET) at different treatment time points remains controversial. This study aimed to evaluate the prognostic value of Deauville score (DS)-based iPET2 and iPET4 in newly diagnosed DLBCL.
Methods: A total of 276 consecutive patients with newly diagnosed DLBCL who received frontline immunochemotherapy(R-CHOH, DA-EDOCH-R or Pola-R-CHP) were prospectively enrolled in the study from the National Longitudinal Cohort of Hematological Diseases (NICHE) at the Blood Diseases Hospital from October 2022 to December 2024. All iPET scans were interpreted according to the Deauville score (DS): iPET-positive (iPET+, DS 4–5) and iPET-negative (iPET−, DS 1–3). Kaplan-Meier survival analysis and Cox proportional hazards regression models were performed to evaluate the prognostic significance of iPET2 and iPET4.
Results: With a median follow-up of 27 months (range, 2–44 months), the 2-year PFS and OS rates of the entire cohort were 81.0% and 90.2%, respectively. Among 236 patients with evaluable iPET2, the iPET2+ group (n=70) demonstrated significantly inferior outcomes versus the iPET2− group (n=166): EOT-PET complete remission (CR) rate (73.7% vs 96.9%, P<0.0001), 2-year PFS (64.8% vs 88.8%, HR=3.61, 95%CI: 1.86–7.03, P<0.0001), and 2-year OS (77.0% vs 94.5%, HR=3.94, 95%CI: 1.59–7.75, P=0.0005). For 251 patients with evaluable iPET4, the prognostic discrepancy was more pronounced between the iPET4+ (n=38) and iPET4− (n=213) groups: EOT-PET CR rate (48.8% vs 96.6%, P<0.0001), 2-year PFS (45.5% vs 89.5%, HR=6.97, 95%CI: 2.69–18.05, P<0.0001), and 2-year OS (68.9% vs 94.8%, HR=6.10, 95%CI: 1.73–21.52, P<0.0001).
Subgroup analysis stratified by IPI score showed that in the low-risk cohort (IPI<2), iPET2+ group had significantly inferior 2-year PFS (70.0% vs 98.8%, P<0.0001) and OS (78.5% vs 98.4%, P<0.0001) compared with iPET2- group. Consistently, iPET4+group presented with markedly decreased 2-year PFS (58.3% vs 99.0%, P<0.0001) and OS (74.1% vs 100%, P<0.0001) relative to iPET4-group.In the intermediate-to-high-risk subgroup (IPI≥2), iPET2+ was correlated with poorer 2-year PFS (62.7% vs 79.7%, P=0.0229), while 2-year OS was comparable between iPET2+ and iPET2- patients (76.8% vs 90.6%, P=0.0765). Of note, iPET4+ remained a powerful adverse prognostic factor in this subgroup, with significantly lower 2-year PFS (38.0% vs 81.8%, P<0.0001) and OS (72.5% vs 91.8%, P=0.0063) versus iPET4- patients.
Multivariate Cox regression analysis incorporating IPI, iPET2, and iPET4 confirmed that iPET4 positivity was an independent adverse prognostic factor for PFS (HR=4.27, 95%CI: 1.83–9.81, P=0.0007) and OS (HR=4.88, 95%CI: 1.44–16.90, P=0.0110).
Conclusions: Both DS-based iPET2 and iPET4 effectively predict treatment response and survival outcomes in newly diagnosed DLBCL, with iPET4 positivity serving as a powerful independent poor prognostic factor. The combination of iPET assessment and conventional IPI score significantly refines risk stratification and provides evidence for PET-guided adaptive therapy. Patients with IPI<2 and negative iPET2 achieve excellent prognosis with a 2-year PFS of 98.8%, supporting the feasibility of de-escalated therapy to reduce treatment-related toxicity. In contrast, patients with IPI≥2 and positive iPET4 represent an ultra-high-risk population with a dismal 2-year PFS of 38.0%, for whom early therapeutic escalation is warranted to reverse unfavorable prognosis and improve clinical outcomes.
DISCLOSURES
Changming Dong: No relevant conflicts of interest to declare.